Technical Data
Osteoprotegerin (OPG, Osteoclastogenesis Inhibitory Factor, OCIF)
Human OPG (Osteoprotegerin, also know as OCIF
(Osteoclastogenesis inhibitory factor), is a member of the TNF
receptor superfamily. Recombinant human OPG/OCIF specifically acts on bone tissues and increases bone mineral density and bone volume associated with a decrease of active osteoclast number.

Suitable for use in Flow Cytometry and Immunoprecipitation. Other applications not tested.

Recommended Dilution:
Flow Cytometry: 1:1000.
Immunoprecipitation: 1:200.
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile glycerol (40-50%), aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
MabIgG2a6D633Highly Purified
100ug4C (-20C Glycerol)Blue IceHumanRat
Recombinant human OPG:Fc (osteoprotegerin:Fc). The cysteine-rich region of human OPG (aa 22-202) is fused to the Fc portion of human IgG1.
Purified from concentrated hybridoma tissue culture supernatant. Highly purified (SDS-PAGE).
Supplied as a liquid in PBS, 0.02% sodium azide.
Recognizes human OPG.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Osteoprotegerin: U. Feige; Ann. Rheum. Dis. 60, Suppl 3, iii81 (2001) 2. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells: C.M. Shipman and P.I. Croucher; Cancer Res. 63, 912 (2003)